F
Frank H J van den Hoogen
Researcher at Radboud University Nijmegen
Publications - 105
Citations - 7928
Frank H J van den Hoogen is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Psoriatic arthritis & Rheumatoid arthritis. The author has an hindex of 28, co-authored 98 publications receiving 6508 citations. Previous affiliations of Frank H J van den Hoogen include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Bashar Kahaleh,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Peter A. Merkel,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value
TL;DR: It is concluded that, at present, the antibody response directed to citrullinated antigens has the most valuable diagnostic and prognostic potential for RA.
Journal Article
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.
Alfons A den Broeder,Marjonne C W Creemers,Jaap Fransen,Eefje de Jong,Dirk-Jan R.A.M. de Rooij,Ate Wymenga,Maarten de Waal-Malefijt,Frank H J van den Hoogen +7 more
TL;DR: Although the study was not powered to detect small differences in infection rates, perioperative continuation of anti-TNF does not seem to be an important risk factor for SSI.
Journal ArticleDOI
Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis
Calin D. Popa,Frank H J van den Hoogen,Timothy R D J Radstake,Mihai G. Netea,Agnes Eijsbouts,Martin den Heijer,Jos W. M. van der Meer,Piet L. C. M. van Riel,Anton F. H. Stalenhoef,Pilar Barrera +9 more
TL;DR: It is concluded that one-year therapy with infliximab is likely to lead to a more pro-atherogenic pattern of the plasma lipids concentrations, however, the overall impact of these changes on the cardiovascular risk is more complex, considering the strong anti-inflammatory effects of anti-TNF drugs.